BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant BRISTOL-MYERS SQUIBB PHARMA EEIG submitted on 29 April 2002 an 
application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal 
Products (EMEA) for REYATAZ, through the centralised procedure. After agreement by the CPMP 
on 26 July 2001 , this medicinal product has been referred to Part B of the Annex to Council 
Regulation No (EEC) 2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. Eric Abadie 
Co-Rapporteur:  Dr. Ian Hudson 
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
The procedure started on 20 May 2002. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  1  August 
2002. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 26 
July 2002. 
During the meeting on 17 – 19 September 2002 the CPMP agreed on the consolidated List of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 20 September 2002. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
14 March 2003. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CPMP members on 2 May 2003. 
During  the  CPMP  meeting  on  20  –  22  May  2003,  the  CPMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant. 
The company submitted the responses to list of outstanding issues on 1 September 2003. 
The  Rapporteurs  circulated  the  Joint  Review  on  the  applicant’s  responses  to  the  List  of 
outstanding Issues to all CPMP members on 9 October 2003. 
During the CPMP meeting on 21 - 22 October 2003, outstanding issues were addressed by the 
applicant during a hearing before the CPMP on 22 October 2003. 
During  the  meeting  on  18  –  20  November  2003,  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  under  exceptional  circumstances  to  REYATAZ  on 
20 November 2003. The applicant provided the letter of undertaking on the follow-up measures 
to be fulfilled post-authorisation on 19 November 2003. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 2 March 2004. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
